The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech ...

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, ...

The plans, if implemented, would result in the layoff of about 365 employees. Galapagos said it will still entertain ...

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Cost Plus Drugs is sharing pricing data with TrumpRx, the administration’s new direct-to-consumer prescription drug website ...

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and ...

The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.